Cell viability assays in TWT and non-TWT cell lines with either ATM, NBN, or MRE11 knocked out revealed that melanoma cell lines lacking the expression of these genes are sensitive to olaparib, and warrant a more exhaustive follow-up to determine whether PARP inhibitors may benefit molecularly stratified melanoma patients in the clinic. The gene discussed is NBN; the disease is melanoma.